Carotid body tumor screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 13: | Line 13: | ||
**Patients with multiple paragangliomas | **Patients with multiple paragangliomas | ||
{{Family tree/start}} | {{Family tree/start}} | ||
{{Family tree | | | | | | | | | | | | A01 | | | |A01= Patient with carotid body tumor}} | {{Family tree | | | | | | | | | | | | A01 | | | |A01= Patient with [[carotid body]] [[tumor]]}} | ||
{{Family tree | | | | | | | | | | | | |!| | | | | }} | {{Family tree | | | | | | | | | | | | |!| | | | | }} | ||
{{Family tree | | | | | | | | | | | | B01 | | | |B01= History, Physical examination, and evaluation of cnotralateral side}} | {{Family tree | | | | | | | | | | | | B01 | | | |B01= History, [[Physical examination]], and evaluation of [[cnotralateral]] side}} | ||
{{Family tree | | | | | | | | | |,|-|-|^|-|-|.| | }} | {{Family tree | | | | | | | | | |,|-|-|^|-|-|.| | }} | ||
{{Family tree | | | | | | | | | C01 | | | | C02 |C01= Patients with age < 50 years<br>Patients with multiple paraganglioma<br>Patients with a positive family history| C02= The rest of the patients}} | {{Family tree | | | | | | | | | C01 | | | | C02 |C01= Patients with age < 50 years<br>Patients with multiple [[paraganglioma]]<br>Patients with a positive family history| C02= The rest of the patients}} | ||
{{Family tree | | | | | | | | | |!| | | | }} | {{Family tree | | | | | | | | | |!| | | | }} | ||
{{Family tree | | | | | | | | | D01 | | | | | |D01= SDHD genetic testing}} | {{Family tree | | | | | | | | | D01 | | | | | |D01= [[SDHD]] [[genetic]] testing}} | ||
{{Family tree | | | | | |,|-|-|-|^|-|-|.| | }} | {{Family tree | | | | | |,|-|-|-|^|-|-|.| | }} | ||
{{Family tree | | | | | E01 | | | | | E02 |E01= Presence of SDHD mutation |E02= Absence of SDHD mutation}} | {{Family tree | | | | | E01 | | | | | E02 |E01= Presence of [[SDHD]] [[mutation]] |E02= Absence of [[SDHD]] [[mutation]]}} | ||
{{Family tree | | | | | |!| | | | | | |!| | | | | }} | {{Family tree | | | | | |!| | | | | | |!| | | | | }} | ||
{{Family tree | | | | | |!| | | | | | F01 | | | |F01= SDHC and SDHB genetic testing}} | {{Family tree | | | | | |!| | | | | | F01 | | | |F01= [[SDHC]] and [[SDHB]] [[genetic]] testing}} | ||
{{Family tree | | | | | |!| | | |,|-|-|^|-|-|.| | }} | {{Family tree | | | | | |!| | | |,|-|-|^|-|-|.| | }} | ||
{{Family tree | | | | | |!| | | G01 | | | | G02 |G01= Presence of SDHC/ | {{Family tree | | | | | |!| | | G01 | | | | G02 |G01= Presence of [[SDHC]]/[[SDHB]] [[mutation]] |G02= Absence of [[SDHC]]/[[SDHB]] [[mutation]]}} | ||
{{Family tree | | | | | |!| | | |!| | }} | {{Family tree | | | | | |!| | | |!| | }} | ||
{{familytree | | | | | | H02 |-|'| | | |H02=All the relatives should be evaluated for the presence of paragnaglioma}} | {{familytree | | | | | | H02 |-|'| | | |H02=All the relatives should be evaluated for the presence of [[paragnaglioma]]}} | ||
{{Family tree | | | | | | |!| | | | }} | {{Family tree | | | | | | |!| | | | }} | ||
{{Family tree | | | | | | I01 | | | |I01= whole-body F-dihydroxyphenylalanine (F-DOPA) positron emission tomography to assess the presence of other paragangliomas}} | {{Family tree | | | | | | I01 | | | |I01= whole-body F-dihydroxyphenylalanine (F-DOPA) [[positron emission tomography]] to assess the presence of other [[paragangliomas]]}} | ||
{{Family tree | | | |,|-|-|^|-|-|.| |}} | {{Family tree | | | |,|-|-|^|-|-|.| |}} | ||
{{Family tree | | | J01 | | | | J02 |J01= Presence of other paraganglioma |J02= Absence of other paraganglioma}} | {{Family tree | | | J01 | | | | J02 |J01= Presence of other [[paraganglioma]] |J02= Absence of other [[paraganglioma]]}} | ||
{{Family tree | | | |!| | | | | |!| | | }} | {{Family tree | | | |!| | | | | |!| | | }} | ||
{{Family tree | | | K01 | | | | K02 |K01= 24-hour urine catecholamines and MRI for biochemical screening|K02=surveillance screening every 5 years}} | {{Family tree | | | K01 | | | | K02 |K01= 24-hour urine [[catecholamines]] and [[MRI]] for biochemical [[screening]]|K02=surveillance screening every 5 years}} | ||
{{Family tree/end}} | {{Family tree/end}} | ||
*In case of functional paraganglioma, the patient should receive a-blockade, followed by b-blockade for symptom control before excision of the tumor. | *In case of functional [[paraganglioma]], the patient should receive [[a-blockade]], followed by [[b-blockade]] for [[symptom]] control before excision of the [[tumor]]. | ||
==References== | ==References== | ||
Revision as of 18:09, 15 April 2019
|
Carotid body tumor Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Carotid body tumor screening On the Web |
|
American Roentgen Ray Society Images of Carotid body tumor screening |
|
Risk calculators and risk factors for Carotid body tumor screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2]
Overview
There is insufficient evidence to recommend routine screening for the carotid body tumor. However, patients who manifested the symptoms before the age of 50 years old, those with a positive family history and those with multiple paragangliomas has been recommended to undergo additional testing.
Screening
- There is insufficient evidence to recommend routine screening for the carotid body tumor. However, it has been recommended that the following patients should undergo additional evaluations:[1]
- Patients younger than 50 years of age
- Patients with a positive family history for paraganglioma
- Patients with multiple paragangliomas
| Patient with carotid body tumor | |||||||||||||||||||||||||||||||||||
| History, Physical examination, and evaluation of cnotralateral side | |||||||||||||||||||||||||||||||||||
| Patients with age < 50 years Patients with multiple paraganglioma Patients with a positive family history | The rest of the patients | ||||||||||||||||||||||||||||||||||
| SDHD genetic testing | |||||||||||||||||||||||||||||||||||
| Presence of SDHD mutation | Absence of SDHD mutation | ||||||||||||||||||||||||||||||||||
| SDHC and SDHB genetic testing | |||||||||||||||||||||||||||||||||||
| Presence of SDHC/SDHB mutation | Absence of SDHC/SDHB mutation | ||||||||||||||||||||||||||||||||||
| All the relatives should be evaluated for the presence of paragnaglioma | |||||||||||||||||||||||||||||||||||
| whole-body F-dihydroxyphenylalanine (F-DOPA) positron emission tomography to assess the presence of other paragangliomas | |||||||||||||||||||||||||||||||||||
| Presence of other paraganglioma | Absence of other paraganglioma | ||||||||||||||||||||||||||||||||||
| 24-hour urine catecholamines and MRI for biochemical screening | surveillance screening every 5 years | ||||||||||||||||||||||||||||||||||
- In case of functional paraganglioma, the patient should receive a-blockade, followed by b-blockade for symptom control before excision of the tumor.
References
- ↑ Davila, Victor J.; Chang, James M.; Stone, William M.; Fowl, Richard J.; Bower, Thomas C.; Hinni, Michael L.; Money, Samuel R. (2016). "Current surgical management of carotid body tumors". Journal of Vascular Surgery. 64 (6): 1703–1710. doi:10.1016/j.jvs.2016.05.076. ISSN 0741-5214.